Passive immune therapy (also called as convalescent therapy, antibody infusion and serum therapy) refers to an infectious disease treatment that transfuses convalescent blood product from survivors to other patients. This treatment has been widely applied in the pre-antibiotic era (1890--1930s) ([@bib23]). Modern use of convalescent therapy consists of blood products in the forms of screened whole blood, convalescent plasma, hyperimmune globulins (HIG/IVIG), and monoclonal antibody (MoAb), where HIG and MoAb are both derived from plasma through rigorous medical processes. HIG has been actively applied in the treatment of many bacterial and viral diseases, such as tetanus, hepatitis A/B, rabies, measles, complications of smallpox vaccination ([@bib20]). In addition, convalescent therapy has a strong track record of success in treating emerging infections such as H1N1, Spanish Influenza, severe acute respiratory syndrome (SARS), and Chikungunya ([@bib21], [@bib25], [@bib26], [@bib12]), and is considered as a potential treatment option for H5N1, middle east respiratory syndrome (MERS), and Ebola ([@bib25], [@bib5], [@bib35]).

Convalescent blood transfusion was used with success as a treatment in a group of 8 Ebola patients during the 1995 Kikwit Ebola outbreak ([@bib28]): after the treatment, only 1 patient (12.5%) died. With no licensed medicine or vaccine for Ebola, convalescent blood transfusion was the only treatment approved by World Health Organization (WHO) and there are increasing interests in its use ([@bib18], [@bib35], [@bib34], [@bib7]).

In September 2014, [@bib35] issued an interim guidance on use of convalescent whole blood or plasma collected from Ebola virus disease survivors for transfusion during outbreaks, and provided detailed guidelines on donor selection, screening, donation and handling of blood and plasma units, and transfusion therapy. This interim guidance points out a dynamic treatment--donation--stockpile positive feedback cycle: transfused patients survive from Ebola, convalescent survivors become donors and make donation to the blood bank, the blood bank storage is affected by the current blood usage and donation, and the blood bank level in turn determines the number of transfused patients.

Modeling the use of passive-immunotherapy during an infectious disease outbreak was previously studied in [@bib37], in which a differential equation model was formatted to investigate the logistical feasibility of collecting convalescent plasma to treat severe cases of pandemic influenza in Hong Kong. This study assumes that only 0.5% of all infected cases are severe cases who are not expected to make donation after recovery, so the blood donation must be obtained from survivors of non-severe cases. Unlike pandemic influenza, Ebola is a fatal disease with a death ratio of 70% ([@bib22]) and all cases receiving palliative care are severe. Therefore, with an urgent need of convalescent treatment in a large-scale population, all survivors are considered as potential donors. Moreover, for some developing countries with limited resources such as those in West Africa, blood donations are likely to expire quickly with underrated storage condition. With these concerns, we propose a model for convalescent treatment in a population that is applicable in epidemic outbreaks when no other treatment strategies are available.

We develop a mathematical model that incorporates the treatment--donation--stockpile dynamics, and addresses two important questions relevant to a potential large scale Ebola outbreak and convalescent blood transfusion treatment: to what extent the case fatality ratio (CFR) can be reduced by using convalescent blood transfusion as the empiric therapy; and what would be an optimal treatment--donation--stockpile strategy that can sustain a rapid and effective implementation of treatment plans ([@bib34]).

The transmission dynamics of 2014--2015 West Africa Ebola outbreak have been well studied in [@bib36], [@bib10], [@bib11], [@bib29], [@bib31], [@bib27], [@bib15], [@bib1], and [@bib17]. Possible containment and surveillance strategies have been modeled and evaluated ([@bib9], [@bib33]). [@bib19] proposed a model to evaluate the large-scale use of convalescent therapy, but the model is different from ours. Comparisons between the two models will be discussed in [Section 5](#s0025){ref-type="sec"}.

An objective of our study here is to inform a rational distribution strategy of inadequate resource in order to balance between reducing the CFR and maintaining a reasonable level of convalescent blood bank storage for other priority considerations. Our model simulations show that in a setting similar to the 2014--2015 Ebola outbreak in Guinea (with a total population of 12-million, a final case count of 3810, and an overall CFR of 67% ([@bib8]), if the public health system is well developed to be able to handle a total of 200 patients with convalescent blood transfusion as an empiric therapy, then at the end of an outbreak, the Ebola CFR can be reduced to less than 57%. Our simulation also shows that the efficiency in switching from palliative care to blood transfusion treatment is essential for the treatment outcome: a 10-day delay increases the overall CFR by more than 5%.

1. The model {#s0005}
============

To model the treatment--donation--stockpile dynamics, we assume that the convalescent therapy is initiated as the empirical therapy at the beginning of an Ebola outbreak, and the community has a developed public health system for complete isolation in hospitals and proper handling of dead bodies both inside and outside hospitals. These assumptions can be relaxed, as will be discussed later, to allow more complicated transmission dynamics than we model in this paper. We assume further that Ebola patients become contagious upon onset of symptoms.

To establish the model, we first classify the population into the following 9 classes ([Fig. 1](#f0005){ref-type="fig"} ): susceptible (*S*), infected in latent period (*L*), infectious and symptomatic but still unidentified (*I*), identified patients receiving palliative care (*P*), identified patients receiving convalescent therapy (*T*), convalescent patients discharged from hospital (*R*), first-time and multi-time potential donors who can immediately make donations ($D_{1}$ and $D_{m}$), and potential donors in recovery period after their latest donation ($D_{0}$).Fig. 1Flow diagram of transmission--treatment-donation-stockpile dynamics. Susceptible people become infected. Identified infectives are isolated and treated with palliative care. Each patient in palliative care is considered to switch to blood transfusion therapy at a constant rate *η*, and the percentage of those who are selected to receive blood transfusion depends on the blood bank stockpile and the blood bank stockpile usage strategy. Patients under blood transfusion and palliative care have different probabilities to survive. Convalescent patients discharged from hospitals need to wait for an average of $\sigma^{- 1}$ days to be considered as potential donors. Donors will be considered again as potential donors *τ* days after their latest donation.

Our transmission--treatment--donation--stockpile dynamics model, given in the Appendix, follows the schematic diagram in [Fig. 1](#f0005){ref-type="fig"} and tracks the blood bank stock level (*B*). Previous modelling studies on Ebola outbreaks mainly considered the infection dynamics in systems involving the 3 compartments $S,L,I$ (left boxes of [Fig. 1](#f0005){ref-type="fig"}) or their variations. Our model focuses on the treatment--donation--stockpile dynamics, which involves the remaining compartments in [Fig. 1](#f0005){ref-type="fig"}.

The three compartments *S*(*t*), *L*(*t*), and *I*(*t*) form a subsystem about the disease transmission dynamics. We take into consideration of the fact that the disease transmission rate is reduced due to the enforcement of a series of public health interventions (other than convalescent treatment) throughout the outbreak ([@bib1], [@bib32]), and we set the transmission rate at time *t* from the beginning of the outbreak as $\beta\left( t \right)$ in Eqs. [(1)](#eq0005){ref-type="disp-formula"}, [(2)](#eq0010){ref-type="disp-formula"} in the section of Appendix. We will discuss the choice of this transmission rate and its relationship to the basic and effective reproduction numbers in the following section.

We shall use the standard assumptions provided in the WHO׳s interim guidance ([@bib35]):•On average, convalescent therapy takes one unit of blood donation to treat one Ebola patient.•Potential donors are defined as those Ebola survivors who have been discharged from hospitals for more than a certain number of days (28 days as suggested by [@bib35]).•After each donation, the donor is required to wait for a certain number of days for next donation.•There is a constant loss rate of donors for various reasons such as donors׳ health conditions, and loss of contacts.•Blood donation in the blood bank has a constant storage expiration rate.

To develop specific strategies on the deployment of blood transfusion therapy, we further assume the following:•Identified infected individuals will be hospitalized, and then first receive palliative care. All the patients in palliative care request for convalescent therapy, but only part of them will receive the therapy according to daily blood bank stock levels and the deployment strategy adopted.•Blood bank storage might be inadequate at any stage, specially at the beginning of the outbreak, so the ratio of patients switching to the convalescent therapy is affected by the stock level and given by $B\left( t \right)/\left( B\left( t \right) + K \right)$ at time *t*, where *K* is the threshold level of the stock when half of the patients receive the therapy -- a higher value of *K* corresponds to a more conservative use of the stockpile.We emphasize that this model framework is appropriate when the public health system is enhanced to ensure that the assumed isolation, treatment and stockpile measures can be implemented. Possible variations of the model setting in the case when this assumed public health enhancement is not met will be discussed in the final discussion section.

Under an outbreak scenario, we use the model to evaluate how the following aspects are determined by different treatment policies including initial blood stockpile: (1) daily patient population under convalescent therapy and palliative care -- the requirement on hospital facility and personnel; (2) cumulative CFR -- the effectiveness of convalescent therapy; (3) daily blood bank levels and the minimum level during the entire outbreak -- number of stockpiles available for other control priorities; and (4) loss of blood donation due to expiration -- storage waste.

2. Parameters in the model {#s0010}
==========================

We categorize the parameters involved in our model based on the disease epidemiology, implementation logistics and their impact on final outcomes.

*Disease transmission parameters*: Parameters *N* (total population), *β* (infection transmission rate function), *ρ* (transition rate from latent to infectious period), *κ* (case identification rate), and *μ* (death rate of unidentified individuals) are related to the epidemiological characteristics of the disease spread.

We adopt the results in [@bib1], with the assumption that the transmission rate decays exponentially at rate *r* due to public health interventions, and set $\beta\left( t \right) = \beta_{0}\ \exp\left( - \mathit{rt} \right),\ t \geq 0$, where *β* ~0~ is the initial transmission rate. From our model equations [(1)](#eq0005){ref-type="disp-formula"}, [(2)](#eq0010){ref-type="disp-formula"}, [(3)](#eq0015){ref-type="disp-formula"} in the section of Appendix, which are the same as in [@bib1], the basic reproduction number of the disease is given by $R_{0} = \beta_{0}/\left( \mu + \kappa \right)$, and the effective reproduction number at any time $t > 0$ is given by $R_{e}\left( t \right) = \beta\left( t \right)/\left( \mu + \kappa \right)$.

*Treatment strategy parameters*: The management of the two available treatments, convalescent therapy and palliative care, depends on the values of parameters: *η* (rate of switching treatment from palliative care to convalescent therapy), *K* (a parameter relevant to the stockpile usage strategy), $\gamma_{T}$ and $\gamma_{P}$ (discharge rates of patients under blood transfusion and under palliative care, respectively), $\mu_{T}$ and $\mu_{P}$ (death rates of patients under blood transfusion and under palliative care, respectively). The initial stockpile level $B\left( 0 \right)$ will be treated as a parameter, which affects the initial treatment strategy and the subsequent potential donors from the first generation of disease cases.

We explain more about the parameter *η* here. Depending on the current blood bank level, only a portion of the patients under palliative care can be switched to blood transfusion treatment. In reality, *η* reflects the rate of blood bank storage update and blood delivery to hospitals. For example, $\eta = 1$ means a daily update of blood bank storage and delivery of blood units. Hence, the patients under palliative care are considered to switch to blood treatment everyday, but only some can be switched based on the daily blood bank level and the stockpile usage strategy.

*Blood donation parameters*: Parameters relevant to blood collection and expiration policies are *σ* (transition rate from discharged patients to potential donors), *ϵ* (percentage of survivors who are qualified for donation), *α* (blood donation rate of donors), *ω* (inflow rate of donation to blood bank), *ξ* (loss rate of donors), *τ* (donor recovery period between donations), and *λ* (expiration rate of donated blood).

3. Methods for simulation of the model {#s0015}
======================================

We set up the model parameters (relevant to transmission dynamics) and initial conditions to closely mimic the actual Ebola outbreak in Guinea with a total population of 12 millions, that is, $N = 12 \times 10^{6}$. Since we have used the decaying transmission rate to reflect the impact of other intervention measures on transmission dynamics, we will focus on the impact of convalescent treatment on CFR reduction when all infected cases are identified and receive palliative care. Hence the death rate *μ* of unidentified cases is assumed to be zero. As reported in [@bib35], the mean time from symptom onset to case identification is around 5 days, so we let $\kappa = 0.2$.

We use the estimation results for Guinea in [@bib1]: the basic reproduction number *R* ~0~ is estimated to be 1.51, and the rate *r*=0.0023 at which control measures reduce transmission. The value of *β* ~0~ and the transmission rate function *β* are determined by *R* ~0~, *r*, *κ*, and *μ* in the above settings. The robustness of the results is discussed via sensitivity analysis in [Fig. 8](#f0040){ref-type="fig"}.

There is no evidence shown that successful blood transfusion can shorten the recovery period of a patient. Hence, we assume that the average time for hospitalization is 20 days, which coincides with that of [@bib28]. If the hospitalization period of a patient with palliative care alone is $1/\gamma_{P}$, then for patients switch from palliative care to convalescent therapy, we can use the equation $1/\eta + 1/\gamma_{T} = 1/\gamma_{P}$ to estimate the value $\gamma_{T}$. In our simulations, we will also set $\mu_{P} = 3\gamma_{P}/7,\mu_{T} = \gamma_{T}/7$ to reflect the death ratios under two different treatments, one is 70% for palliative care ([@bib22]) and the other is 12.5% for blood transfusion treatment ([@bib28]).

We assume $\alpha = \omega$, which means that all donated blood are handled properly and the wasted blood is solely due to the expiration. The ranges of $\alpha\left( = \omega \right)$ and *ξ* are obtained by estimating possible ranges of the corresponding daily percentages of donors who make donations, and donors who lost contact, as shown in [Table 1](#t0005){ref-type="table"} .Table 1Parameter values for [Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}, [Fig. 6](#f0030){ref-type="fig"}, [Fig. 7](#f0035){ref-type="fig"}, [Fig. 8](#f0040){ref-type="fig"}. Most of the fixed parameters are taken from the references ([@bib1], [@bib28], [@bib35], [@bib36], [@bib11], [@bib13], [@bib22]).**Transmission**Value**Treatment**Value**Donation**Value*N*$12 \times 10^{6}$$\gamma_{T}$0.053 ${day}^{- 1}$*σ*1/28 ${day}^{- 1}$$\beta\left( t \right)$$\kappa \cdot R_{0} \cdot \exp\left( - 0.0023t \right)$$\gamma_{P}$0.05 ${day}^{- 1}$*α*$- \ln\left( {1 - p_{d}} \right)\ {day}^{- 1}$$1/\rho$11.4 days$\mu_{T}$$3\gamma_{T}/7$*ω*Same as *ακ*0.2 ${day}^{- 1}$$\mu_{P}$$3\gamma_{P}/7$*ξ*$- \ln\left( {1 - p_{c}} \right)\ {day}^{- 1}$*μ*0.0 ${day}^{- 1}$*η*1.0 ${day}^{- 1}$$p_{d}$90%[a](#tblfn1){ref-type="table-fn"}*R*~0~1.51*K*1--500 units[a](#tblfn1){ref-type="table-fn"}$p_{c}$10%[a](#tblfn1){ref-type="table-fn"}B(0)0--200 units[a](#tblfn1){ref-type="table-fn"}$\tau$56 days to 16 wks for CWB2 wks for CP$1/\lambda$35 days for CWB40 days for CP*ϵ*50%[a](#tblfn1){ref-type="table-fn"}[^1][^2]

As an illustration, we show how to estimate the value *α*. We consider a group of donors, denoted by *D*(*t*) at time *t*, who never lose contacts, and the only loss rate is due to donation. Hence, $D^{\prime}\left( t \right) = - \alpha D\left( t \right)$ for $t \geq 0$ and $D\left( t \right) = D\left( 0 \right)\exp\left( - \alpha t \right)$. It follows that the percentage of donors who donate in a certain day from time *t* to $t + 1$ is $p_{d} = 1 - D\left( t + 1 \right)/D\left( t \right) = 1 - \exp\left( - \alpha \right)$ and $\alpha = - \ln\left( 1 - p_{d} \right)$.

4. Simulation results {#s0020}
=====================

We fit the transmission dynamics of Ebola in Guinea in [Fig. 2](#f0010){ref-type="fig"} , with initially 21 infectious cases, and 1 recovered case. Note that the transmission dynamics is not affected by the treatment, but the case fatality will be subject to the treatment--donation--stockpile dynamics. All simulations are performed under the assumption that the use and collection of convalescent blood starts at the beginning of the outbreak.Fig. 2A fitted outbreak scenario for Guinea. Assume 21 initial infectious case, and 1 recovered case. The transmission dynamics is not affected by the treatment, but the case fatality will be subject to the treatment--donation--stockpile dynamics. (a) Daily infectious population. (b) Cumulative infected cases.

*Convalescent whole blood or plasma*: [Fig. 3](#f0015){ref-type="fig"} compares the blood collection and storage in two different forms: convalescent whole blood (CWB) and convalescent plasma (CP), as suggested in [@bib35]. We set the donor recovery period for CWB as 56 days -- the shortest recommended period for whole blood donors, and for CP as 14 days; the blood collection expiration period is 35 days for CWB and 40 days for CP. The simulation clearly shows substantial advantage of convalescent plasma treatment in terms of reducing the CFR ([Fig. 3](#f0015){ref-type="fig"}c) and increasing the blood bank stockpile ([Fig. 3](#f0015){ref-type="fig"}d). Logistic consideration of different therapies will need a further cost--benefit study based on our model formulation. Note that a significant difference in the amount of expired stockpiles ([Fig. 3](#f0015){ref-type="fig"}f) is mainly caused by the higher amount of blood donation in the form of CP ([Fig. 3](#f0015){ref-type="fig"}d) since there will be more recovered patients and donors from the CP therapy.Fig. 3Comparison of the use of convalescent whole blood (CWB) and convalescent plasma (CP): (1) the donor recovery period is 56 days for CWB donors and 14 days for CP donors; and (2) the blood collection expiration period is 35 days for CWB and 40 days for CP. The simulation clearly shows substantial advantage of convalescent plasma treatment in terms of reducing the CFR ([Fig. 3](#f0015){ref-type="fig"}c) and increasing the blood bank stockpile ([Fig. 3](#f0015){ref-type="fig"}d). (a) Patients under transfusion treatment. (b) Patients under palliative care. (c) Overall CFR. (d) Blood bank stockpile level. (e) Potential donors. (f) Cumulative expired stockpiles.

*Initial stockpile and blood stockpile usage strategy*: [Fig. 4](#f0020){ref-type="fig"} examines the impact on CFR and implication for the need of capacity of the public health system to implement different stockpile usage strategies by varying *K*, where larger *K* corresponds to more conservative use of stockpiles. This simulation is based on convalescent plasma therapy and the assumption that a blood stockpile of 100 units is available at the beginning of the outbreak. Aggressive use of blood storage indeed leads to lower CFR throughout the outbreak ([Fig. 4](#f0020){ref-type="fig"}c), but also results in low blood storage level for a long time ([Fig. 4](#f0020){ref-type="fig"}d). Conservative use of stockpile maintains higher blood bank levels for most of the time, but leads to large amount of donation waste ([Fig. 4](#f0020){ref-type="fig"}f). So in either case, it might be also necessary to utilize and process the expiring donations into HIG blood product for use during emergency events.Fig. 4Comparison among different stockpile usage strategies--variations of *K*. Recall that a large *K* value means more conservative usage of the stockpile. This simulation is based on convalescent plasma therapy and the assumption that a blood stockpile of 100 units is available at the beginning of the outbreak. [Fig. 4](#f0020){ref-type="fig"}c shows that more conservative use of blood storage leads to higher CFR in the early stage of the outbreak, and the CFR decreases faster later on due to more stockpiles become available. (a) Patients under transfusion treatment. (b) Patients under palliative care. (c) Overall CFR. (d) Blood bank storage. (e) Potential donors. (f) Cumulative expired stockpiles.

In [Fig. 5](#f0025){ref-type="fig"} , we illustrate the impact of initial stockpiles $B(0)$. The simulation is based on convalescent plasma therapy and on the assumption that a stockpile preservation policy with threshold of 200 stockpiles under which half of the patients will switch to blood transfusion. In a large-scale convalescent therapy program, the availability of more stockpiles at the beginning leads to lower CFR during the early stage of the outbreak, but the overall CFR is not affected much. However, impact of insufficient initial stockpile $B(0)$ could be different from outbreaks in a small population, to address this small-scale outbreak requires agent-based simulations in a future study.Fig. 5Comparison among different initial stockpiles-- variations of $B\left( 0 \right)$. The simulation is based on convalescent plasma therapy and on the assumption that a stockpile preservation policy with threshold of 20 stockpiles under which half of the patients will switch to blood transfusion. (a) Patients under transfusion treatment. (b) Patients under palliative care. (c) Overall CFR. (d) Blood bank storage. (e) Potential donors. (f) Cumulative expired stockpiles.

In [Fig. 6](#f0030){ref-type="fig"} , we consider the impact on CFR when the values *K* and $B\left( 0 \right)$ are changed. We note that the final CFR over the entire period of the outbreak is not considerably affected by either of the two aspects, and the minimal stockpile number is small in all cases. The above results suggest us to investigate the impacts of the blood collection parameters on reducing CFRs and maintaining blood bank levels.Fig. 6Impact of varying *K* and $B\left( 0 \right)$ on the CFR and minimum stockpile. We fix all other parameters as in [Table 1](#t0005){ref-type="table"} for CP therapy, except *K* and $B\left( 0 \right)$. We report the cumulative CFR and the minimum stockpile throughout the outbreak. (a) Minimum amount of blood bank stockpiles. (b) Final CFR.

*Management of blood collection services*: We vary the parameter values relevant to blood donation policy and service in [Fig. 7](#f0035){ref-type="fig"} one by one, while keeping all other parameters fixed as in [Table 1](#t0005){ref-type="table"} and consider the treatment and collection in the form of plasma. Parameters suggested in the WHO guideline are marked in the figures. Efficient reduction of the CFR depends significantly on the following aspects: enhancing the policy and service on donation, encouraging and recruiting donors, keeping good track of donor contacts, frequently updating stockpile information and rapid delivery, shortening the donor recovery period, and reducing the transition duration from discharge to first donation. We note that the outcomes are very sensitive to the parameter *α*, *ξ*, and *ϵ*. Hence in real applications of this model, these parameters should be carefully estimated from local blood donation data.Fig. 7Impact of different levels of blood donation policies and implementation -- variations of blood donation relevant parameters. We report the simulations based on convalescent plasma with $K = 50,\ B\left( 0 \right) = 10$. Parameters suggested in the WHO guideline are marked in the figures. Great reductions of the CFR depend significantly on the following aspects: enhancing the policy and service on donation, encouraging and recruiting donors, keeping good track of donor contacts, frequently updating stockpile information and rapid delivery, shortening the donor recovery period, and reducing the transition duration from discharge to first donation. (a) *α* -- donation rate. (b) *ξ* -- loss rate of donors. (c) *τ* -- donor recovery period. (d) $\sigma^{- 1}$ -- duration from discharge to donation. (e) $\eta^{- 1}$ -- delay of switching treatment. (f) *ϵ* -- percentage of qualified survivors.

However, similar to the results in [Fig. 6](#f0030){ref-type="fig"}b, the lowest blood bank levels are not essentially affected by the blood collection parameters and always stay at a low level. Therefore, following our simulation results, to save a sufficient amount of stockpiles for other control priorities, one needs to either hold the stockpiles at a certain threshold level until additional donations are made by recovered patients, or make use of the expiring blood donations.

5. Summary and discussions {#s0025}
==========================

At the initial stage of an emerging infectious disease like Ebola, convalescent therapy is a major treatment option in the absence of licensed medicine or vaccine. Public health authorities should plan with caution about blood transfusion services and develop an informed optimal strategy to both reduce the CFR and maintain the blood bank level that meets the need of other control priorities.

Managing effective blood transfusion services during an outbreak when $R_{0} > 1$ requires comprehensive understanding of the complex treatment--donation--stockpile dynamics: the use of donated blood for treatment reduces the blood stockpile immediately, but the treatment increases the chance for patient recovery, and the recovered patients increase the donation to the blood bank for future treatments. We have developed a mathematical model to examine the outcome of the treatment--donation--stockpile dynamics under different blood service strategies including that described in the WHO interim guidance.

We conclude in our simulations that the use of blood transfusion can significantly reduce the CFR if the use and collection of convalescent plasma start at the beginning of the outbreak. Providing such service does not require a large amount of hospital beds in our setting when other interventions have already reduced the number of infectious cases under palliative care. In our simulations, the number of patients receiving treatment at the peak time is less than 200 ([Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}). The efficiency of implementing blood transfusion treatment and blood collection, and keeping track of donors is of importance for the outcome ([Fig. 7](#f0035){ref-type="fig"}). Establishing sufficient initial stockpile helps with reducing CFR at the early stage of the outbreak, but the overall outcome is not sensitive to the initial amount of stockpiles ([Fig. 5](#f0025){ref-type="fig"}). Aggressive use of blood donations would definitely help achieve the lowest overall CFR, but the blood bank storage level may remain at very low levels in the first half of the outbreak ([Fig. 4](#f0020){ref-type="fig"}), so we may have to consider the use of the expiring blood donations into products as HIG for emergency use.

In our sensitivity analysis shown in [Fig. 8](#f0040){ref-type="fig"} , our aforementioned observations are shown to be valid for a range of basic reproduction numbers (1.2--1.7), death ratio of blood treatment (5--30%), death ratio of palliative care (60--80%), average length of hospital stay after blood treatment (10--40 days), average length of hospital stay with palliative care (15--40 days), and percentage of survivors who are qualified for donation (20--80%).Fig. 8Sensitivity analysis for the variations in the final CFR and minimal stockpile level based on different values of *R*~0~. We here fix $K = 50,\ B\left( 0 \right) = 10$. We sample the parameters in larger ranges: death ratio of blood treatment (5--30%), death ratio of palliative care (60--80%), average length of hospital stay after blood treatment (10--40 days), average length of hospital stay with palliative care (15--40 days), and percentage of survivors who are qualified for donation (20--80%).

Our modeling analysis is based on a homogeneous population and we assume that every identified patient has equal chance of switching from palliative care to convalescent therapy. Detailed information about disease progression in individuals is needed to guide the model design with further stratification of the population into finer compartments to develop the priority list of patients for the blood transfusion treatment. Again, this issue needs to be considered within the complex treatment--donation--stockpile dynamics.

We conclude that convalescent plasma treatment is more efficient in reducing the CFR and boosting blood bank storage than convalescent whole blood treatment. Additionally, we should note that there will be logistic consideration for each treatment option or their combination which requires a further cost--benefit study. We stress that convalescent whole blood treatment is effective for reducing the CFR as shown in [Fig. 3](#f0015){ref-type="fig"}, and every effort should be made to implement this if convalescent plasma treatment is difficult to achieve.

Our modeling framework assumes an improved public health system for effective identification and isolation, so as to identify symptomatic patients at an early stage. Modifications of the framework are needed to address disease transmission and management scenarios in countries where this assumption is not met ([@bib16], [@bib6], [@bib2], [@bib14], [@bib4], [@bib30]). Compared with the work in [@bib19], our model possesses the following features of the blood transfusion dynamics. (1) Our model contains a treatment decision period upon hospital admission, and reflects the fact that every hospitalized patient can be considered for blood transfusion regardless of their current length of stay. In this way, the probability for a patient to receive blood transfusion depends on the blood bank level during the whole period of their hospital stay. (2) We model the recovery time from the most recent donation by the delay suggested by [@bib35], so that the period between the current and forthcoming donation could follow a distribution of lags with a lowest value of *τ* days. (3) More importantly, the strategy for distributing blood stockpiles is modeled with a function involves both of the up-to-date blood bank level and a measurement of the decision on preserving stockpiles for emergency purposes. This function can be easily modified with specific stockpile deployment policies, and our model is suitable for evaluating relevant future treatment plans.

As asymptomatic close contacts might provide a potential resource for convalescent blood donation ([@bib3]), contact tracing and surveillance should be enhanced. As other infection control measures including isolation, contact tracing ([@bib33]) and early diagnosis ([@bib9]) all contribute to shortening the switching time from palliative care to blood transfusion treatment, an integrated strategy of Ebola control must incorporate the consideration of blood transfusion services. All of these infection control measures are implicitly incorporated into the decaying transmission rate of the model ([@bib1]) we have adopted. Incorporating these measures explicitly in our model will only require appropriate modifications in the disease transmission dynamics $\left( S,L,I \right)$-components.

The use of convalescent serum has a long history ([@bib23], [@bib24]), and blood transfusion can be the first available treatment option when little is known about an emerging infectious disease. We believe that our study can also be used with necessary modifications to inform integrated control programs for many other emerging and re-emerging infectious diseases.

Appendix A. Model equations {#s0030}
===========================

The mathematical model we establish is governed by the following system of 10 first-order differential equations. The first three equations describe the disease transmission dynamics only involving $S,L,I$ compartments in [Fig. 1](#f0005){ref-type="fig"}.$$S^{\prime}\left( t \right) = - \beta\left( t \right)S\left( t \right)\frac{I\left( t \right)}{N}$$ $$L^{\prime}\left( t \right) = \beta\left( t \right)S\left( t \right)\frac{I\left( t \right)}{N} - \rho L\left( t \right)$$ $$I^{\prime}\left( t \right) = \rho L\left( t \right) - \left( \kappa + \mu \right)I\left( t \right)$$The last 7 equations model the treatment--donation--stockpile dynamics, where a delayed subsystem is introduced and contains a delay *τ* (days) for survived patients to make subsequent donations. $$P^{\prime}\left( t \right) = \kappa I\left( t \right) - \left( \gamma_{P} + \mu_{P} \right)P\left( t \right) - \frac{B\left( t \right)}{B\left( t \right) + K}\left( {\eta P\left( t \right)} \right)$$ $$T^{\prime}\left( t \right) = \frac{B\left( t \right)}{B\left( t \right) + K}\left( {\eta P\left( t \right)} \right) - \left( \gamma_{T} + \mu_{T} \right)T\left( t \right)$$ $$R^{\prime}\left( t \right) = \gamma_{T}T\left( t \right) + \gamma_{P}P\left( t \right) - \sigma R\left( t \right)$$ $$D_{1}^{\prime}\left( t \right) = \epsilon\sigma R\left( t \right) - \left( \alpha + \xi \right)D_{1}\left( t \right)$$ $$D_{0}^{\prime}\left( t \right) = - e^{- \xi\tau}\alpha\left\lbrack D_{1}\left( t - \tau \right) + D_{m}\left( t - \tau \right) \right\rbrack - \xi D_{0}\left( t \right) + \alpha\left\lbrack D_{1}\left( t \right) + D_{m}\left( t \right) \right\rbrack$$ $$D_{m}^{\prime}\left( t \right) = e^{- \xi\tau}\alpha\left\lbrack D_{1}\left( t - \tau \right) + D_{m}\left( t - \tau \right) \right\rbrack - \left( \alpha + \xi \right)D_{m}\left( t \right)$$ $$B^{\prime}\left( t \right) = \omega\left\lbrack D_{1}\left( t \right) + D_{m}\left( t \right) \right\rbrack - \frac{B\left( t \right)}{B\left( t \right) + K}\left( {\eta P\left( t \right)} \right) - \lambda B\left( t \right)$$
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[^1]: CWB: convalescent whole blood; CP: convalescent plasma.

[^2]: Assumed values.
